Avava

About Avava

Avava, Inc. is a medical aesthetics technology company that operates on a platform business model, providing advanced intradermal laser products for dermatological treatments. The company was founded in 2016 by Dr. R. Rox Anderson, Dr. Dieter Manstein, and Dr. Henry Chan, all distinguished figures in the field of dermatology and laser medicine. Dr. Anderson, a trailblazer in laser treatments and the inventor of selective photothermolysis, brings decades of pioneering research from his work at the Wellman Center for Photomedicine at Massachusetts General Hospital, a teaching affiliate of Harvard Medical School. The company was launched out of Blossom Innovations, a dermatology incubator, with a mission to address the limitations of existing laser technologies.

Avava's business is centered on the development and commercialization of its flagship product line, which includes the MIRIA system. This system is sold to dermatology clinics, plastic surgeons, and other medical spa professionals. The company's revenue is generated through the sale of these medical devices and likely involves consumables and servicing contracts. A significant milestone was achieved in June 2024, when Avava secured $35 million in financing, combining a $25 million Series C round and $10 million in growth capital, to accelerate the commercialization of MIRIA and support global expansion.

The core of Avava's product offering is its proprietary Focal Point Technology™, which allows for precise delivery of laser energy to specific depths within the skin, from the epidermis to the deep dermis, while minimizing damage to surrounding tissue. This technology is a key differentiator, enabling safer and more effective treatments for a variety of skin conditions, including acne scarring, benign pigmented lesions, hyperpigmentation, wrinkles, and fine lines. A critical advantage is its suitability for all Fitzpatrick skin types (I-VI), addressing a significant gap in the market for patients with darker skin tones who are often at higher risk with conventional lasers. The system integrates several features for enhanced patient experience and clinical efficiency, such as ComfortCool™ for patient comfort, AVAVASite™ for high-resolution imaging and treatment mapping, and an ergonomically designed weightless handpiece. In April 2025, the U.S. Food and Drug Administration (FDA) cleared Avava's laser for treating acne scars, a clearance based on a multi-center clinical trial where over 90% of subjects showed visible improvement.